Toronto, Ontario — November 5, 2025 — Leads & Copy —
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) will present full data from its ARCHER Phase II clinical trial at the European Society of Cardiology meeting in Trieste, Italy, on November 29, 2025.
The presentation, delivered by Dr. Leslie T. Cooper, Jr. of the Mayo Clinic, is expected to detail CardiolRx™’s effects on myocardial inflammation and remodeling, including a reduction in left ventricular mass.
A webcast conference call will be hosted on December 1, 2025, to discuss the ARCHER findings and their significance.
According to Dr. Andrew Hamer, the ESC M&PD meeting is an important global forum that unites leading clinicians and scientists advancing the understanding and treatment of myocarditis, pericarditis, and other inflammatory heart diseases. He is honored to have Dr. Cooper present the ARCHER results at this prestigious meeting dedicated to myopericardial diseases.
David Elsley, President and CEO of Cardiol Therapeutics, stated that these findings represent the first evidence of a drug’s efficacy on structural recovery and reverse remodeling in this patient population.
ARCHER enrolled 109 patients from leading cardiovascular research centers in the United States, France, Brazil, and Israel and investigated the safety, tolerability, and impact of CardiolRx™ on myocardial recovery in patients presenting with acute myocarditis.
Webcast Conference Call Information
Cardiol will host a webcast conference call at 8:30 a.m. EST on December 1, 2025, following the presentation at the ESC M&PD meeting. Members of the Company’s management team will discuss the clinical findings of the ARCHER trial, implications for future development, and next steps in advancing Cardiol’s programs in inflammatory heart disease. To participate by telephone, please dial 877-346-6112 (Canada and the United States) or +1-848-280-6350 (International). The conference call with also be broadcast live online through a listen-only webcast (with slides), which will be posted under “Events & Presentations” in the Investors section of the Cardiol website and archived for approximately 90 days.
Contact:
Investor.relations@cardiolrx.com
Source: Cardiol Therapeutics Inc.
